Adaptive resistance to RAF inhibitors in melanoma

Pigment Cell and Melanoma Research

Volumn 27, Issue 6, 2014, Pages 1032-1038

  Kugel, Curtis H ^a,b   Aplin, Andrew E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adaptive; BRAF V600E; Dabrafenib; Vemurafenib

Indexed keywords

B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; B RAF KINASE; PROTEIN KINASE INHIBITOR;

AEROBIC METABOLISM; CELL SURVIVAL; ENZYME ACTIVATION; HUMAN; MELANOMA; MELANOMA CELL; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; PATHOLOGY; SKIN NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 84911428488     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12264     Document Type: Review

References (46)

1. Abel, E.V., Basile, K.J., Kugel, C.H. III et al. (2013). Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J. Clin. Invest. 123, 2155-2168.
2. Basile, K.J., Abel, E.V., and Aplin, A.E. (2012). Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31, 2471-2479.
3. Chakrabarty, A., Sanchez, V., Kuba, M.G., Rinehart, C., and Arteaga, C.L. (2012). Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl Acad. Sci. USA 109, 2718-2723.
4. Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P.K., Baselga, J., and Rosen, N. (2011). AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71.
5. Corcoran, R.B., Ebi, H., Turke, A.B. et al. (2012). EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235.
6. Curry, J.L., Torres-Cabala, C.A., Kim, K.B., Tetzlaff, M.T., Duvic, M., Tsai, K.Y., Hong, D.S., and Prieto, V.G. (2013). Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int. J. Dermatol. 53, 376-384.
7. Das Thakur, M., Salangsang, F., Landman, A.S., Sellers, W.R., Pryer, N.K., Levesque, M.P., Dummer, R., McMahon, M., and Stuart, D.D. (2013). Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251-255.
8. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
9. Dykens, J.A., and Will, Y. (2007). The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 12, 777-785.
10. Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
11. Gala, K., and Chandarlapaty, S. (2014). Molecular pathways: HER3 targeted therapy. Clin. Cancer Res. 20, 1410-1416.
12. Gopal, Y.N.V., Deng, W., Woodman, S.E., Komurov, K., Ram, P., Smith, P.D., and Davies, M.A. (2010). Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in BRAF-mutant human cutaneous melanoma cells. Cancer Res. 70, 8736-8747.
13. Haq, R., Shoag, J., Andreu-Perez, P. et al. (2013). Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 23, 302-315.
14. Hartsough, E., Shao, Y., and Aplin, A.E. (2013). Resistance to RAF inhibitors revisited. J. Invest. Dermatol. 134, 319-325.
15. Hartsough, E.J., Basile, K., and Aplin, A.E. (2014). Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol. Cancer Res. 5, 795-802.
16. Heidorn, S.J., Milagre, C., Whittaker, S. et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221.
17. Kim, H.J., and Bar-Sagi, D. (2004). Modulation of signalling by Sprouty: a developing story. Nat. Rev. Mol. Cell Biol. 5, 441-450.
18. Kolch, W. (2005). Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol. 6, 827-837.
19. Kopetz, S., Desai, J., Chan, E., Hecht, J.R., O'Dwyer, P.J., Lee, R.J., Nolop, K.B., and Saltz, L. (2010). PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28(Suppl 15), [abstract# 3534].
20. Lito, P., Pratilas, C.A., Joseph, E.W. et al. (2012). Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668-682.
21. Montero-Conde, C., Ruiz-Llorente, S., Dominguez, J.M., Knauf, J.A., Viale, A., Sherman, E.J., Ryder, M., Ghossein, R.A., Rosen, N., and Fagin, J.A. (2013). Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 3, 520-533.
22. Moreno-Sánchez, R., Rodríguez-Enríquez, S., Marín-Hernández, A., and Saavedra, E. (2007). Energy metabolism in tumor cells. FEBS J. 274, 1393-1418.
23. Morrison, D.K. (2001). KSR: a MAPK scaffold of the Ras pathway? J. Cell Sci. 114, 1609-1612.
24. Muranen, T., Selfors Laura, M., Worster Devin, T., Iwanicki Marcin, P., Song, L., Morales Fabiana, C., Gao, S., Mills Gordon, B., and Brugge Joan, S. (2012). Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21, 227-239.
25. Nazarian, R., Shi, H., Wang, Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
26. Owens, D.M., and Keyse, S.M. (2007). Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26, 3203-3213.
27. Papa, S., Martino, P., Capitanio, G., Gaballo, A., Rasmo, D., Signorile, A., Petruzzella, V. (2012). The oxidative phosphorylation system in mammalian mitochondria. In Advances in Mitochondrial Medicine, Scatena R et al., eds. (the Netherlands: Springer Netherlands), pp. 3-37.
28. Paraiso, K.H.T., Xiang, Y., Rebecca, V.W. et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760.
29. Poulikakos, P.I., Persaud, Y., Janakiraman, M. et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390.
30. Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A., and Bernards, R. (2012). Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103.
31. Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B., and Rosen, N. (2009). V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl Acad. Sci. USA 106, 4519-4524.
32. Roesch, A., Vultur, A., Bogeski, I. et al. (2013). Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B high cells. Cancer Cell 23, 811-825.
33. Salama, A.K.S., and Flaherty, K.T. (2013). BRAF in melanoma: current strategies and future directions. Clin. Cancer Res. 19, 4326-4334.
34. Sergina, N.V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K.M., and Moasser, M.M. (2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441.
35. Serra, V., Scaltriti, M., Prudkin, L. et al. (2011). PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30, 2547-2557.
36. Shao, Y., and Aplin, A.E. (2010). Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 70, 6670-6681.
37. Sharma, S.V., Lee, D.Y., Li, B. et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80.
38. Shi, F., Telesco, S.E., Liu, Y., Radhakrishnan, R., and Lemmon, M.A. (2010). ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl Acad. Sci. USA 107, 7692-7697.
39. Shi, H., Hong, A., Kong, X. et al. (2013). A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 4, 69-79.
40. Smalley, K.S.M., Haass, N.K., Brafford, P.A., Lioni, M., Flaherty, K.T., and Herlyn, M. (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5, 1136-1144.
41. Sosman, J.A., Kim, K.B., Schuchter, L. et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
42. Sun, C., Wang, L., Huang, S. et al. (2014). Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118-122.
43. Villanueva, J., Vultur, A., Lee, J.T. et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
44. Warburg, O. (1956). On the origin of cancer cells. Science 123, 309-314.
45. Wilson, K.J., Gilmore, J.L., Foley, J., Lemmon, M.A., and Riese Ii, D.J. (2009). Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol. Ther. 122, 1-8.
46. Yan, Y., Serra, V., Prudkin, L. et al. (2013). Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clin. Cancer Res. 19, 6976-6986.